Published in Indian J Psychiatry on January 01, 2010
Guillain-Barré syndrome following zimeldine treatment. J Neurol Neurosurg Psychiatry (1985) 1.08
Antipsychotic drugs, neurotransmitters, and schizophrenia. Am J Psychiatry (1978) 1.07
Does dopamine play a role in schizophrenia? Psychol Med (1977) 1.02
Biogenic amines in human brain in normal aging, senile dementia, and chronic alcoholism. Adv Biochem Psychopharmacol (1980) 0.97
The influence of nerve-impulse flow on the synthesis and metabolism of 5-hydroxytryptamine in the central nervous system. Biochem Soc Symp (1972) 0.91
Thirty years of dopamine research. Adv Neurol (1993) 0.91
Brain neurotransmitters in aging and dementia: similar changes across diagnostic dementia groups. Gerontology (1987) 0.84
Basic concepts underlying recent developments in the field of Parkinson's disease. Contemp Neurol Ser (1971) 0.84
Speculations on the control of mental and motor functions by dopamine-modulated cortico-striato-thalamo-cortical feedback loops. Mt Sinai J Med (1988) 0.83
Modeling sensitization to stimulants in humans: an [11C]raclopride/positron emission tomography study in healthy men. Arch Gen Psychiatry (2006) 1.78
Rapid improvement of acute schizophrenia symptoms after intravenous sodium nitroprusside: a randomized, double-blind, placebo-controlled trial. JAMA Psychiatry (2013) 1.56
Functional neuroimaging of minocycline's effect in a patient with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry (2010) 1.43
Bioactive contaminants leach from disposable laboratory plasticware. Science (2008) 1.42
Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry (2014) 1.39
Serine racemase is associated with schizophrenia susceptibility in humans and in a mouse model. Hum Mol Genet (2009) 1.18
Non-linear complexity measures of heart rate variability in acute schizophrenia. Clin Neurophysiol (2007) 1.17
Adult ADHD and its comorbidities, with a focus on bipolar disorder. J Affect Disord (2009) 1.12
Impaired neurosteroid synthesis in multiple sclerosis. Brain (2011) 1.05
Mood-elevating effects of d-amphetamine and incentive salience: the effect of acute dopamine precursor depletion. J Psychiatry Neurosci (2007) 1.03
Monoamine oxidase inhibition during brain development induces pathological aggressive behavior in mice. Biol Psychiatry (2002) 1.03
Discriminative stimulus effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans trained to discriminate among d-amphetamine, meta-chlorophenylpiperazine and placebo. Drug Alcohol Depend (2005) 1.02
The antipsychotic potential of l-stepholidine--a naturally occurring dopamine receptor D1 agonist and D2 antagonist. Psychopharmacology (Berl) (2008) 1.00
Effects of caffeine on heart rate and QT variability during sleep. Depress Anxiety (2005) 1.00
Decreasing amphetamine-induced dopamine release by acute phenylalanine/tyrosine depletion: A PET/[11C]raclopride study in healthy men. Neuropsychopharmacology (2004) 1.00
Glutamate system, amyloid ß peptides and tau protein: functional interrelationships and relevance to Alzheimer disease pathology. J Psychiatry Neurosci (2013) 0.99
Genetic inactivation of D-amino acid oxidase enhances extinction and reversal learning in mice. Learn Mem (2008) 0.98
Glia contribute to the purinergic modulation of inspiratory rhythm-generating networks. J Neurosci (2010) 0.98
Determination of d-serine and related neuroactive amino acids in human plasma by high-performance liquid chromatography with fluorimetric detection. J Chromatogr B Analyt Technol Biomed Life Sci (2006) 0.98
Nonlinear measures of respiration: respiratory irregularity and increased chaos of respiration in patients with panic disorder. Neuropsychobiology (2002) 0.96
Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: a preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects. J Clin Psychiatry (2002) 0.95
Influence of olanzapine on QT variability and complexity measures of heart rate in patients with schizophrenia. J Clin Psychopharmacol (2008) 0.94
Interactions between the cytochrome P450 system and the second-generation antipsychotics. J Psychiatry Neurosci (2003) 0.93
Heart rate and QT interval variability: abnormal alpha-2 adrenergic function in patients with panic disorder. Psychiatry Res (2003) 0.93
Synthesis, transport, and metabolism of serotonin formed from exogenously applied 5-HTP after spinal cord injury in rats. J Neurophysiol (2013) 0.91
Decreased coherence in higher frequency ranges (beta and gamma) between central and frontal EEG in patients with schizophrenia: A preliminary report. Psychiatry Res (2005) 0.91
Influence of age on linear and nonlinear measures of autonomic cardiovascular modulation. Ann Noninvasive Electrocardiol (2010) 0.90
The antidepressant phenelzine protects neurons and astrocytes against formaldehyde-induced toxicity. J Neurochem (2010) 0.89
D-serine and schizophrenia: an update. Expert Rev Neurother (2012) 0.88
A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder. J Clin Psychiatry (2002) 0.88
Impaired hippocampal LTP in inbred mouse strains can be rescued by beta-adrenergic receptor activation. Eur J Neurosci (2007) 0.87
Increased glutamate levels in the medial prefrontal cortex in patients with postpartum depression. Neuropsychopharmacology (2012) 0.87
Relationship of plasma amphetamine levels to physiological, subjective, cognitive and biochemical measures in healthy volunteers. Hum Psychopharmacol (2003) 0.86
Increased cholesterol levels during paroxetine administration in healthy men. J Clin Psychiatry (2003) 0.85
The MAO inhibitor phenelzine improves functional outcomes in mice with experimental autoimmune encephalomyelitis (EAE). Brain Behav Immun (2011) 0.85
Paroxetine-induced increase in metabolic end products of nitric oxide. J Clin Psychopharmacol (2003) 0.84
The interplay of cannabinoid and NMDA glutamate receptor systems in humans: preliminary evidence of interactive effects of cannabidiol and ketamine in healthy human subjects. Prog Neuropsychopharmacol Biol Psychiatry (2010) 0.84
Increased pulse-wave velocity in patients with anxiety: implications for autonomic dysfunction. J Psychosom Res (2006) 0.84
Neurosteroid-mediated regulation of brain innate immunity in HIV/AIDS: DHEA-S suppresses neurovirulence. FASEB J (2012) 0.84
Effect of D-amphetamine on inhibition and motor planning as a function of baseline performance. Psychopharmacology (Berl) (2010) 0.84
Neurochemical effects of the monoamine oxidase inhibitor phenelzine on brain GABA and alanine: A comparison with vigabatrin. J Pharm Pharm Sci (2008) 0.84
Paroxetine decreases respiratory irregularity of linear and nonlinear measures of respiration in patients with panic disorder. A preliminary report. Neuropsychobiology (2004) 0.83
Increased beat-to-beat QRS amplitude variability in patients with congestive cardiac failure. Int J Cardiol (2006) 0.83
Reinforcing effects of diazepam under anxiogenic conditions in individuals with social anxiety. Exp Clin Psychopharmacol (2005) 0.83
An update on amine oxidase inhibitors: multifaceted drugs. Prog Neuropsychopharmacol Biol Psychiatry (2013) 0.82
Comorbid attention deficit/hyperactivity disorder and substance use disorder: treatment considerations. Curr Drug Abuse Rev (2012) 0.82
Multiple 5-HT receptors are involved in the effects of acute MDMA treatment: studies on locomotor activity and responding for conditioned reinforcement. Psychopharmacology (Berl) (2002) 0.82
The effects of a low protein diet on amino acids and enzymes in the serine synthesis pathway in mice. Amino Acids (2009) 0.81
Paroxetine-induced increase in metabolic end products of nitric oxide. J Clin Psychopharmacol (2003) 0.81
Fluoxetine, but not sertraline or citalopram, potentiates the locomotor stimulant effect of cocaine: possible pharmacokinetic effects. Psychopharmacology (Berl) (2004) 0.81
Role of serotonin (5-HT) in the antidepressant-like properties of neuropeptide Y (NPY) in the mouse forced swim test. Peptides (2005) 0.81
Mean and variability of QT-interval: Relevance to psychiatric illness and psychotropic medication. Indian J Psychiatry (2009) 0.81
Neuroactive steroids and anxiety disorders. J Psychiatry Neurosci (2002) 0.81
Amine oxidases and their inhibitors: what can they tell us about neuroprotection and the development of drugs for neuropsychiatric disorders? J Psychiatry Neurosci (2007) 0.80
Determination of L-serine-O-phosphate in rat and mouse brain tissue using high-performance liquid chromatography and fluorimetric detection. Anal Biochem (2010) 0.80
Reduced cardio-respiratory coupling indicates suppression of vagal activity in healthy relatives of patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry (2010) 0.80
Zero net flux estimates of septal extracellular glucose levels and the effects of glucose on septal extracellular GABA levels. Eur J Pharmacol (2009) 0.80
Monoamine oxidase inhibitors and neuroprotection: a review. Am J Ther (2012) 0.80
Major depression: the relative contribution of gender, MDMA, and cannabis use. Depress Anxiety (2008) 0.80
HIV protease inhibitors disrupt astrocytic glutamate transporter function and neurobehavioral performance. AIDS (2016) 0.79
Effect of lamotrigine on plasma GABA levels in healthy humans. Prog Neuropsychopharmacol Biol Psychiatry (2003) 0.79
Quantification of l-stepholidine in rat brain and plasma by high performance liquid chromatography combined with fluorescence detection. J Chromatogr B Analyt Technol Biomed Life Sci (2006) 0.79
Effects of the antidepressant/antipanic drug phenelzine and its putative metabolite phenylethylidenehydrazine on extracellular gamma-aminobutyric acid levels in the striatum. Biochem Pharmacol (2002) 0.79
Exaggerated beat-to-beat R amplitude variability in patients with panic disorder after intravenous isoproterenol. Neuropsychobiology (2007) 0.79
Tissue concentration changes of amino acids and biogenic amines in the central nervous system of mice with experimental autoimmune encephalomyelitis (EAE). Neurochem Int (2011) 0.78
Individual differences in frontal cortical thickness correlate with the d-amphetamine-induced striatal dopamine response in humans. J Neurosci (2013) 0.78
The impact of stress and psychosocial interventions on assisted reproductive technology outcome. J Sex Marital Ther (2011) 0.78
Metabolic syndrome: relevance to antidepressant treatment. J Psychiatry Neurosci (2006) 0.78
Augmentation of clozapine partial responders with conventional antipsychotics. Schizophr Res (2003) 0.78
L-Serine-O-phosphate in the central nervous system. Brain Res (2009) 0.78
The pharmacology and formulation of paliperidone extended release. Expert Rev Neurother (2012) 0.78
Exaggerated differences in pulse wave velocity between left and right sides among patients with anxiety disorders and cardiovascular disease. Psychosom Med (2007) 0.78
Recent developments in the regulation of monoamine oxidase form and function: is the current model restricting our understanding of the breadth of contribution of monoamine oxidase to brain [dys]function? Curr Top Med Chem (2012) 0.77
Linear and nonlinear measures of blood pressure variability: increased chaos of blood pressure time series in patients with panic disorder. Depress Anxiety (2004) 0.77
Phenelzine causes an increase in brain ornithine that is prevented by prior monoamine oxidase inhibition. Neurochem Res (2007) 0.77
Special issues in the management of depression in women. Can J Psychiatry (2004) 0.77
The MAO inhibitor phenelzine can improve functional outcomes in mice with established clinical signs in experimental autoimmune encephalomyelitis (EAE). Behav Brain Res (2013) 0.77
Monoamine oxidase inhibitors, their structural analogues, and neuroprotection. Indian J Exp Biol (2004) 0.77
Nitric oxide plasma/serum levels in patients with schizophrenia: a systematic review and meta-analysis. Rev Bras Psiquiatr (2012) 0.77
Nefazodone in the treatment of generalized social phobia: a randomized, placebo-controlled trial. J Clin Psychiatry (2007) 0.77
Nitric oxide: a key player in the relation between cardiovascular disease and major depressive disorder? J Psychiatry Neurosci (2004) 0.77
The effects of chronic administration of inhibitors of flavin and quinone amine oxidases on imidazoline I(1) receptor density in rat whole brain. Ann N Y Acad Sci (2003) 0.77
The effects of sodium nitroprusside treatment on cognitive deficits in schizophrenia: a pilot study. J Clin Psychopharmacol (2015) 0.77
Cardiac risk and schizophrenia. J Psychiatry Neurosci (2005) 0.77
Long-term effects of fluoxetine or vehicle administration during pregnancy on behavioral outcomes in guinea pig offspring. Psychopharmacology (Berl) (2004) 0.76
Brain activation patterns in women with acquired hypoactive sexual desire disorder and women with normal sexual function: a cross-sectional pilot study. Fertil Steril (2013) 0.76
Sodium nitroprusside treatment of clozapine-refractory schizophrenia. J Clin Psychopharmacol (2014) 0.76
Targeting the NMDA receptor-nitric oxide-cyclic GMP pathway to develop non-dopaminergic antipsychotic medications for schizophrenia. Rev Bras Psiquiatr (2011) 0.76
The story of antipsychotics: Past and present. Indian J Psychiatry (2010) 0.76
Determination of rat hepatic polyamines by electron-capture gas chromatography. J Pharmacol Toxicol Methods (2004) 0.76
Metabolism of N-methyl, N-propargylphenylethylamine: studies with human liver microsomes and cDNA expressed cytochrome P450 (CYP) enzymes. Cell Mol Neurobiol (2006) 0.76
Glycine reuptake inhibition: a promising therapeutic strategy in the treatment of schizophrenia? Future Med Chem (2013) 0.76
Effects of pregabalin on behavioral alterations induced by ketamine in rats. Rev Bras Psiquiatr (2012) 0.75
Effects of acute 3,4-methylenedioxymethamphetamine on sleep and daytime sleepiness in MDMA users: a preliminary study. Sleep (2009) 0.75
Clozapine treatment of patients with refractory schizophrenia, concurrent dengue infection and hematological abnormalities: three case reports. Ther Adv Psychopharmacol (2013) 0.75
Allosteric modulation of semicarbazide-sensitive amine oxidase activities in vitro by imidazoline receptor ligands. Br J Pharmacol (2004) 0.75
Annual high-dose vitamin D supplementation does not affect mental well-being in older women. Evid Based Ment Health (2011) 0.75